Hailey Bio invests 200 million yuan to set up merger and acquisition fund

Pharmaceutical Network January 23, January 21 news, A-share listed company "Haili Bio" issued "on the proposed establishment of mergers and acquisitions fund and related transactions" said that it intends to invest in Shanghai Ranju Investment Management Partnership (tentative name), Zhang Haiming, Shanghai Fengxian Biotech Park Development Co., Ltdand other investors jointly launched the establishment of an industrial merger and acquisition fund "Shanghai Runyu Investment Partnership" (tentative name)According to the announcement, the launch of the Shanghai Runyu Investment Partnershipenterprise, the survival period of 7 years, the first 4 years for the investment period, the next 3 years for the exit period, the main investment will not be limited to life sciences, medicalhealthrelated areas involved, the investment of equity can be through IPO, new three board listing, the company acquisition or transfer to other third parties and other ways to withdrawin the partner situation, the proposed fund raising of 500 million yuan, of which Haili Bio as a limited partner to pay the capital contribution amount of not more than 200 million yuan, Shanghai Fengxian Biotech Park Development Co., Ltdand Zhang Haiming as a limited partner respectively proposed to pay the capital contribution amount of 100 million yuan each, Shanghai Ranyu Investment Management Partnership as the general partner of the executive services, the intention to pay the capital contribution of 10 million yuan, the rest of the shares to other investorsin the management of management, the Shanghai Runyu Investment Partnership under the Investment Decision Committee, the committee is composed of 5 members, of which shanghai Ranyu Investment Management Partnership appointed 3 members, Haili Bio appointed 1 member, Shanghai Fengxian Park Development Co., Ltdappointed 1 member, of which Haili Bio appointed members have a vetois worth noting that Shanghai Fengxian Biotech Park Development Co., Ltdis a subsidiary of the Shanghai Fengxian District State-owned Assets Supervision and Administration Commission, this time as a limited partner of the Shanghai Runxian Investment Partnership, representing the Fengxian District Government's support for the company's transformation and developmentit is understood that Hailey Bio is a research and development, production, sales, service in one of the specialized veterinary biological products production enterprises, founded in 1981, 2015 landed in the domestic A-share main board market, with 11GMPproduction lines, independent production of livestock, poultry two series of more than 40 productsOn September 7, 2016, Hailey Bio held the 18th meeting of the company's second board of directors to consider and approve the "On the Company's investment in Shanghai Preconn Medical Technology Co., Ltd and related transactions", to increase the capital of the gene sequencing project "Seikang Medical" by 10 million yuan in cash, and to hold a corresponding 1.19% stake in it According to Haili Bio's "Announcement on Investment in Shanghai Preconn medical technology co., Ltd and related transactions" released on September 8, 2016, It is known that Preconn Medical is a new attempt to enter the human health care and bio-medical industry from the field of animal vaccines, and it is also a useful exploration and attempt to realize the strategic layout of "Dynamic protection and human protection" two-wheel drive, which is conducive to breaking through the existing industry restrictions, further strengthening and upgrading platform announced that Haili Bio set up the Shanghai Runyu Investment Partnership, in order to better take advantage of the booming trend of the capital market, accelerate the pace of development in the construction of a large health platform, promote the "dynamic insurance and people's insurance" two-wheel drive layout, enhance the company's competitiveness and profitability It is conducive to the implementation of capital operations by various resources, and to the transformation and development of investment areas and future strategies